Webinar Date/Time: Wednesday, March 22nd, 2023 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
Are you convinced you have identified your protocol risks and minimized avoidable protocol amendments? Pressure testing with data and analytics will increase your confidence. Discover how in this upcoming webinar.
Register Free:
http://www.appliedclinicaltrialsonline.com/act_w/design_analytics
Event Overview:
Protocol amendments have long been a challenge for the drug development industry given their impact on clinical trial costs and timelines. More than half of finalized protocols undergo an amendment and about half of these are avoidable. Investing in protocol optimization solutions to improve the design process has proven to be essential.
In this webinar, solutions for protocol optimization are shared along with examples demonstrating how IQVIA’s data-informed protocol assessment makes an impact on protocol design by reducing risks that could lead to amendments.
Three key take-aways:
Speakers:
Tammie Nguyen
Design Analytics Director
IQVIA
Tammie Nguyen is a director of clinical planning and design analytics at IQVIA. She has more than 10 years of clinical drug development experience—spanning from strategic design, protocol optimization, and operational planning through execution. Nguyen has completed more than 150 protocol assessments by using data to pressure test protocols, highlighting areas for protocol optimization before operationalization. Nguyen holds a BS in biochemistry and cell biology from the University of California, San Diego, and a PharmD from Northeastern University. In addition, she has completed a post-doctoral fellowship at Eli Lilly and Company, focusing on drug development and trial execution.
Register Free:
http://www.appliedclinicaltrialsonline.com/act_w/design_analytics
Moving Towards Decentralized Elements: Q&A with Scott Palmese, Worldwide Clinical Trials
December 6th 2024Palmese, executive director, site relationships and DCT solutions, discusses the practice of incorporating decentralized elements in a study rather than planning a decentralized trial from the start.